BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022
Bergen, Norway – 28 April 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2022 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2022 in pdf and European Single Electronic Format (ESEF) are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/reports/ Contacts: For